Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Mesoblast Limited (MESO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Mesoblast Limited — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Mesoblast Limited trades at $14.81 (market cap $1.82B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.5× Mesoblast Limited's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| ACAD | MESO | |
|---|---|---|
Market Cap | $4.49B | $1.82B |
Sector | Health | Technology |
52-Week High | $28.06 | $20.96 |
52-Week Low | $20.06 | $10.45 |
Enterprise Value | $3.69B | $1.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).
Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
